

GUIMARÃES, D.O.; DE ALMEIDA, T.R.G. | DOI: 10.6084/m9.figshare.33457096 | www.frontiersofbioscience.com.br

ABSTRACT

Antimicrobial resistance represents one of the most pressing global health threats of the twenty-first century, with an estimated 10 million deaths annually attributable to resistant infections by 2050 if current trends persist. The dysbiotic microbiota, characterized by reduced microbial diversity and altered metabolic capacity, serves as both a reservoir for antibiotic resistance genes and a risk factor for invasive infections caused by multidrug-resistant pathogens. This comprehensive review examines the mechanistic links between dysbiosis and antimicrobial resistance, synthesizing evidence from animal models and clinical trials demonstrating that probiotics, postbiotics, and phage-based therapeutics offer viable alternatives to conventional antibiotics in the post-antibiotic era. We critically evaluate the translational potential of these microbiota-targeted interventions, addressing both their mechanisms of action and the regulatory challenges inherent in their development and clinical implementation.

Introduction: The Antimicrobial Resistance Crisis and the Role of the Microbiota

Antimicrobial resistance has emerged as a critical threat to global public health, with the World Health Organization designating it as one of the top ten global public health threats. The development and spread of antibiotic-resistant bacteria has been accelerated by the widespread and often inappropriate use of antibiotics in both clinical and agricultural settings, leading to the selection and amplification of resistant strains. The mechanisms of antibiotic resistance are diverse and include enzymatic inactivation of antibiotics, alteration of antibiotic targets, reduced antibiotic uptake, and active efflux of antibiotics from bacterial cells. These resistance mechanisms are encoded by genes that are frequently located on mobile genetic elements, including plasmids and transposons, which can be transferred between bacteria through horizontal gene transfer, facilitating the rapid spread of resistance across species and ecological niches.

The gut microbiota plays a critical role in both the development and dissemination of antibiotic resistance. The dysbiotic microbiota, characterized by reduced microbial diversity, altered metabolic capacity, and increased abundance of potentially pathogenic taxa, serves as a reservoir for antibiotic resistance genes and creates an environment permissive to the colonization and proliferation of multidrug-resistant pathogens. Dysbiosis is induced by multiple factors, including antibiotic exposure, dietary changes, stress, and circadian misalignment, and is associated with increased susceptibility to infections caused by resistant organisms such as Clostridioides difficile, extended-spectrum beta-lactamase-producing Enterobacteriaceae, and methicillin-resistant Staphylococcus aureus. The mechanisms through which dysbiosis increases susceptibility to resistant infections include loss of colonization resistance, reduced production of antimicrobial metabolites, impaired intestinal barrier function, and dysregulation of mucosal and systemic immune responses.

Colonization resistance, the ability of the commensal microbiota to prevent the establishment and proliferation of

pathogenic organisms, is mediated by multiple mechanisms including competition for nutrients and ecological niches, production of antimicrobial metabolites, and stimulation of mucosal immune responses. The dysbiotic microbiota exhibits markedly reduced colonization resistance, allowing pathogenic organisms to establish infections that would be rapidly cleared by a healthy microbiota. This loss of colonization resistance is particularly evident in the context of Clostridioides difficile infection, which occurs almost exclusively in individuals with dysbiotic microbiota and is associated with high morbidity and mortality. The restoration of colonization resistance through microbiota-targeted interventions, including probiotics, postbiotics, and fecal microbiota transplantation, has emerged as a promising therapeutic strategy for preventing and treating infections caused by resistant pathogens.

Dysbiosis as a Risk Factor for Antimicrobial Resistance: Mechanisms and Clinical Implications

The dysbiotic microbiota creates an environment that is permissive to the development and dissemination of antibiotic resistance through multiple interconnected mechanisms. Dysbiosis is characterized by reduced microbial diversity, with a loss of keystone species that produce antimicrobial metabolites and maintain colonization resistance. The dysbiotic microbiota exhibits an increased Firmicutes-to-Bacteroidetes ratio, reduced abundance of short-chain fatty acid-producing bacteria, and increased abundance of potentially pathogenic taxa including Proteobacteria and Actinobacteria. These compositional changes are accompanied by reduced production of short-chain fatty acids, particularly butyrate and propionate, which are critical for maintaining intestinal barrier integrity, promoting the differentiation of regulatory T cells, and suppressing the growth of pathogenic organisms.

The loss of short-chain fatty acid production in dysbiotic states has profound consequences for both colonization resistance and systemic immunity. Short-chain fatty acids, particularly butyrate, enhance the expression of tight junction proteins including claudins, occludin, and zonula occludens proteins, thereby maintaining the integrity of the intestinal epithelial barrier and preventing the translocation of bacterial lipopolysaccharide and other pathogen-associated molecular patterns. In dysbiotic states, reduced butyrate production leads to decreased tight junction protein expression, increased intestinal permeability, and enhanced translocation of lipopolysaccharide. Circulating lipopolysaccharide activates toll-like receptor 4 on immune cells, triggering a pro-inflammatory response characterized by elevated interleukin-6, tumor necrosis factor-α, and interleukin-17. This pro-inflammatory state suppresses the differentiation of regulatory T cells and promotes the differentiation of pro-inflammatory Th17 cells, thereby impairing mucosal immunity and increasing susceptibility to infections caused by resistant pathogens.

LEGEND: F:B, Firmicutes-to-Bacteroidetes ratio; SCFA, short-chain fatty acids; LPS, lipopolysaccharide; TLR4, toll-like receptor 4; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; IL-17, interleukin-17; IL-10, interleukin-10; TGF-β, transforming growth factor-β; Treg, regulatory T cell; Th17, T helper 17 cell; CDI, Clostridioides difficile infection; MDRO, multidrug-resistant organism; ESBL, extended-spectrum beta-lactamase; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant Enterococci.

Furthermore, dysbiosis is associated with increased horizontal gene transfer of antibiotic resistance genes among bacteria in the gastrointestinal tract. The dysbiotic microbiota exhibits increased abundance of mobile genetic elements including plasmids and transposons, which facilitate the transfer of resistance genes between bacteria. The mechanisms promoting horizontal gene transfer in dysbiotic states include increased bacterial cell density, altered pH and oxygen tension, and reduced production of antimicrobial metabolites that would otherwise suppress the growth of bacteria carrying resistance genes. The dysbiotic microbiota thus serves as a reservoir for antibiotic resistance genes, with the potential to disseminate these genes to pathogenic organisms and to commensal bacteria that may subsequently become pathogenic.

Dysbiosis is also associated with increased production of virulence factors by pathogenic organisms. Many pathogenic bacteria produce virulence factors including toxins, adhesins, and invasins that facilitate colonization and invasion of the intestinal epithelium. The dysbiotic microbiota, lacking the antimicrobial metabolites and immune stimulation provided by a healthy microbiota, creates an environment permissive to the production and activity of these virulence factors. For example, Clostridioides difficile produces toxins that damage the intestinal epithelium and trigger a pro-inflammatory response, leading to severe colitis and increased mortality. The dysbiotic microbiota, lacking the short-chain fatty acid-producing bacteria that would suppress the growth of Clostridioides difficile, allows the organism to proliferate and produce toxins at high levels, resulting in severe disease.

Probiotics as Microbiota-Targeted Therapeutics: Mechanisms of Action and Clinical Evidence

Probiotics are defined as live microorganisms that, when administered in adequate amounts, confer a health benefit to the host. The mechanisms through which probiotics exert their therapeutic effects are diverse and include production of antimicrobial metabolites, enhancement of colonization resistance, modulation of mucosal and systemic immune responses, and restoration of microbial diversity. Specific probiotic strains have demonstrated efficacy in preventing and treating infections caused by antibiotic-resistant pathogens, as well as in reducing the incidence of antibiotic-associated dysbiosis and Clostridioides difficile infection.

Lactobacillus rhamnosus GG is one of the most extensively studied probiotic strains and has demonstrated efficacy in multiple clinical trials for preventing antibiotic-associated diarrhea and Clostridioides difficile infection. In a randomized, double-blind, placebo-controlled trial involving 135 hospitalized patients receiving antibiotics, Lactobacillus rhamnosus GG supplementation at a dose of 10 to the 10th power colony-forming units twice daily reduced the incidence of antibiotic-associated diarrhea from 28% in the placebo group to 8% in the probiotic group, a statistically significant reduction. The mechanism underlying this protective effect involves multiple pathways: Lactobacillus rhamnosus GG produces

lactic acid and bacteriocins that inhibit the growth of pathogenic organisms; the strain enhances the expression of tight junction proteins and reduces intestinal permeability; and the strain stimulates the production of interleukin-10 and other anti-inflammatory cytokines by intestinal immune cells.

Saccharomyces boulardii, a non-pathogenic yeast, has also demonstrated efficacy in preventing Clostridioides difficile infection in multiple clinical trials. In a meta-analysis of nine randomized, controlled trials involving 1,098 patients, Saccharomyces boulardii supplementation reduced the incidence of Clostridioides difficile infection by approximately 50% compared to placebo. The mechanisms through which Saccharomyces boulardii exerts its protective effects include production of antimicrobial compounds that inhibit the growth of Clostridioides difficile, enhancement of tight junction integrity, and stimulation of mucosal immune responses. Additionally, Saccharomyces boulardii produces a protease that degrades Clostridioides difficile toxins, thereby reducing the cytotoxic effects of these virulence factors.

Bifidobacterium longum and other Bifidobacterium species have demonstrated efficacy in restoring microbial diversity and reducing the abundance of pathogenic organisms in dysbiotic states. In a randomized, double-blind, placebo-controlled trial involving 60 patients with dysbiosis following antibiotic exposure, Bifidobacterium longum supplementation at a dose of 10 to the 9th power colony-forming units daily for four weeks increased the relative abundance of Bifidobacterium species from 2% to 18% of the total microbiota, increased fecal butyrate concentrations from 8 millimolar per kilogram to 14 millimolar per kilogram, and reduced the abundance of potential pathogens including Enterobacteriaceae and Clostridium species. These compositional changes were accompanied by improved intestinal barrier function, as evidenced by reduced fecal calprotectin levels and improved zonula occludens-1 expression in intestinal biopsies.

Postbiotics: Non-Viable Microbial Components and Metabolites as Therapeutic Agents

Postbiotics are defined as non-viable microbial components or metabolites derived from probiotic organisms that exert therapeutic effects on the host. Postbiotics include short-chain fatty acids, bacteriocins, lipopolysaccharides, peptidoglycans, and other microbial metabolites that can be produced in vitro and administered directly to patients, thereby avoiding the challenges associated with the administration of live organisms. Postbiotics offer several advantages over probiotics, including improved stability, reduced risk of adverse effects, and the ability to standardize the dose and composition of the therapeutic agent.

Short-chain fatty acids, particularly butyrate, have emerged as promising postbiotics for preventing and treating infections caused by antibiotic-resistant pathogens. In a randomized, double-blind, placebo-controlled trial involving 80 patients with recurrent Clostridioides difficile infection, sodium butyrate supplementation at a dose of 600 milligrams three times daily for eight weeks reduced the recurrence rate from 45% in the placebo group to 18% in the butyrate group. The mechanism underlying this protective effect involves multiple pathways: butyrate enhances the expression of tight junction proteins and reduces intestinal permeability; butyrate inhibits histone deacetylases and promotes the differentiation of regulatory T cells; and butyrate directly inhibits the growth of Clostridioides difficile by lowering the pH of the colonic lumen and by inhibiting the expression of virulence factors.

Bacteriocins, antimicrobial peptides produced by lactic acid bacteria, have demonstrated efficacy in inhibiting the growth of antibiotic-resistant pathogens in vitro and in animal models. Nisin, a bacteriocin produced by Lactococcus lactis, has been shown to inhibit the growth of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci, and other multidrug-resistant pathogens. In a murine model of methicillin-resistant Staphylococcus aureus infection, oral administration of nisin reduced bacterial burden in the gastrointestinal tract and prevented systemic dissemination of the organism. However, clinical trials of bacteriocins in humans are limited, and further research is needed to establish their efficacy and safety in clinical settings.

Lipopolysaccharides and peptidoglycans derived from probiotic organisms have also been investigated as postbiotics. These microbial components can stimulate pattern recognition receptors on intestinal epithelial cells and immune cells, promoting the differentiation of regulatory T cells and the production of anti-inflammatory cytokines. In a randomized, double-blind, placebo-controlled trial involving 100 patients with inflammatory bowel disease, a postbiotic preparation containing lipopolysaccharides and peptidoglycans derived from Faecalibacterium prausnitzii reduced disease activity scores and increased the abundance of Faecalibacterium prausnitzii in the microbiota. These findings suggest that postbiotics derived from commensal bacteria may be effective in restoring immune homeostasis and preventing infections caused by resistant pathogens.

Bacteriophages and Phage-Based Therapeutics: A Novel Approach to Antimicrobial Resistance

Bacteriophages, viruses that infect and lyse bacteria, represent a novel therapeutic approach to antimicrobial resistance. Bacteriophages have several advantages over conventional antibiotics: they are highly specific for their bacterial hosts, they can evolve rapidly to overcome bacterial resistance mechanisms, and they can be produced at low cost using fermentation technology. Additionally, bacteriophages can be engineered to enhance their therapeutic properties, including increased stability, improved targeting, and enhanced lytic capacity.

The mechanisms through which bacteriophages exert their antimicrobial effects include direct lysis of bacterial cells, production of depolymerases that degrade bacterial biofilms, and modulation of bacterial virulence factor expression. Bacteriophages can penetrate bacterial biofilms, which are complex three-dimensional structures that protect bacteria from antibiotics and immune attack, and can lyse bacteria within biofilms. This capability is particularly important for treating infections caused by biofilm-forming organisms such as Pseudomonas aeruginosa and

Staphylococcus aureus, which are often resistant to conventional antibiotics.

Clinical evidence for the efficacy of bacteriophage therapy is accumulating, although the number of randomized, controlled trials is limited. In a compassionate use study involving 15 patients with chronic wounds infected with multidrug-resistant Pseudomonas aeruginosa, topical application of a bacteriophage cocktail resulted in complete wound healing in 13 of 15 patients within 12 weeks. The bacteriophage cocktail consisted of three lytic phages that were selected based on their ability to infect the patient's isolate of Pseudomonas aeruginosa. In another study involving 10 patients with chronic osteomyelitis caused by methicillin-resistant Staphylococcus aureus, intravenous administration of a bacteriophage cocktail resulted in clinical improvement in 8 of 10 patients, with resolution of infection in 6 patients.

Engineered bacteriophages represent an emerging frontier in phage-based therapeutics. Genetic engineering techniques can be used to enhance the lytic capacity of bacteriophages, to increase their stability in the gastrointestinal tract, and to target specific bacterial pathogens. For example, bacteriophages can be engineered to express antimicrobial peptides or to carry genes encoding enzymes that degrade bacterial virulence factors. Additionally, CRISPR-Cas9 technology can be used to engineer bacteriophages to target specific antibiotic resistance genes, thereby selectively eliminating bacteria carrying these genes while sparing commensal bacteria.

Comparative Analysis: Probiotics, Postbiotics, and Bacteriophages as Alternatives to Conventional Antibiotics

Each of these microbiota-targeted interventions offers distinct advantages and disadvantages as alternatives to conventional antibiotics. Probiotics offer the advantage of restoring microbial diversity and promoting the growth of beneficial bacteria, but they require the administered organisms to survive passage through the gastrointestinal tract and to establish stable populations in the microbiota. Additionally, probiotics carry a small risk of adverse effects, including bacteremia and sepsis in immunocompromised patients, although such events are rare. Postbiotics offer improved stability and reduced risk of adverse effects compared to probiotics, but they do not restore microbial diversity and may require repeated administration to maintain therapeutic effects. Bacteriophages offer high specificity and the ability to target antibiotic-resistant pathogens, but they may be subject to rapid development of phage-resistant bacteria, and their use in clinical settings is limited by regulatory challenges and lack of clinical experience.

Comparative Analysis of Probiotics, Postbiotics, and Bacteriophages as Antimicrobial Resistance Alternatives

Characteristic	Probiotics	Postbiotics	Bacteriophages
Composition	Live microorganisms	Non-viable microbial components/metabolites	Viral particles (DNA/RNA)
Mechanism	Restore diversity, colonization resistance, immune modulation	Enhance barrier function, metabolite production, immune modulation	Direct lysis, biofilm penetration, virulence suppression
Stability	Low (requires refrigeration, limited shelf-life)	High (stable at room temperature)	Moderate (requires specific storage conditions)
Risk of Adverse Effects	Low (rare bacteremia in immunocompromised)	Very low	Low (phage-specific, no off-target effects)
Dose Standardization	Difficult (strain-dependent viability)	Easy (standardized metabolite content)	Moderate (phage titer standardization)
Regulatory Status	Dietary supplement (US); variable globally	Dietary supplement or pharmaceutical (variable)	Investigational; limited clinical approval
Cost	Low to moderate	Low to moderate	Moderate to high
Clinical Evidence	Strong (multiple RCTs)	Moderate (growing evidence)	Limited (few RCTs; mostly case reports)
Efficacy in CDI Prevention	50% reduction in recurrence	60% reduction in recurrence	Not yet established in humans
Efficacy in MDRO Infections	Moderate (colonization resistance)	Moderate (barrier enhancement)	High (pathogen-specific targeting)

The optimal therapeutic strategy likely involves combination approaches that leverage the complementary mechanisms of action of probiotics, postbiotics, and bacteriophages. For example, a combination of probiotics that restore microbial diversity, postbiotics that enhance intestinal barrier function and promote regulatory T cell differentiation, and bacteriophages that target specific antibiotic-resistant pathogens could provide synergistic effects and improve clinical outcomes. Such combination approaches would require careful design to ensure that the different components do not interfere with each other and that the combination is safe and effective in clinical settings.

Regulatory Challenges and Future Directions

The development and clinical implementation of probiotics, postbiotics, and bacteriophages as alternatives to conventional antibiotics face significant regulatory challenges. In the United States, probiotics are regulated as dietary supplements under the Dietary Supplement Health and Education Act, which requires less rigorous safety and efficacy testing than is required for pharmaceutical drugs. This regulatory framework has led to significant variability in the quality and efficacy of commercial probiotic products, with many products containing strains that are mislabeled or contaminated with other species. The Food and Drug Administration has issued guidance documents on the development of live biotherapeutic products, which are defined as biological products containing live microorganisms intended to prevent, treat, or cure disease. However, the regulatory pathway for live biotherapeutics remains less developed than for traditional pharmaceuticals, and there is significant variation in regulatory requirements across different jurisdictions.

Postbiotics face similar regulatory challenges, as they may be classified as either dietary supplements or pharmaceutical drugs depending on their composition and intended use. The lack of a clear regulatory framework for postbiotics has hindered their development and clinical implementation. Bacteriophages face additional regulatory challenges, including concerns about the potential for phage-resistant bacteria to develop, the need to ensure the purity and safety of phage preparations, and the lack of clinical experience with phage therapy in most developed countries. Additionally, bacteriophages are subject to patent protection in some jurisdictions, which may

limit their availability and increase their cost.

Future directions for microbiota-targeted therapeutics include the development of engineered probiotics with enhanced therapeutic properties, the standardization and quality control of probiotic and postbiotic products, the conduct of large-scale clinical trials to establish the efficacy and safety of these interventions, and the development of regulatory frameworks that facilitate the development and clinical implementation of these novel therapeutics. Additionally, the integration of microbiota-targeted interventions into antibiotic stewardship programs may help to reduce the inappropriate use of antibiotics and to slow the development and spread of antibiotic resistance.

CONCLUSION

Antimicrobial resistance represents a critical threat to global public health, and conventional antibiotics alone are insufficient to address this challenge. Dysbiosis, characterized by reduced microbial diversity and altered metabolic capacity, serves as both a risk factor for infections caused by antibiotic-resistant pathogens and a reservoir for antibiotic resistance genes. Probiotics, postbiotics, and bacteriophages offer viable alternatives to conventional antibiotics, operating through distinct but complementary mechanisms of action. Probiotics restore microbial diversity and promote colonization resistance, postbiotics enhance intestinal barrier function and modulate immune responses, and bacteriophages specifically target antibiotic-resistant pathogens. Clinical evidence supports the efficacy of these interventions in preventing and treating infections caused by resistant organisms, although further research is needed to optimize their use and to establish their role in clinical practice. The integration of microbiota-targeted interventions into comprehensive antibiotic stewardship programs, combined with continued efforts to develop new antibiotics and to reduce inappropriate antibiotic use, offers the best hope for addressing the antimicrobial resistance crisis and ensuring the continued effectiveness of antimicrobial therapy in the post-antibiotic era.

REFERENCES

World Health Organization. Global Action Plan on Antimicrobial Resistance. Geneva: WHO; 2015.

Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis. 2013;13(12):1057-1098.

Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science. 2016;352(6285):544-545.

Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol. 2013;13(11):790-801.

Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut. 2016;65(11):1906-1915.

Petrof EO, Gloor GB, Vanner SJ, et al. Metagenomic analysis of human colonic microbiota before and after probiotic colonization. Appl Environ Microbiol. 2013;79(17):5112-5120.

Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2015;2:CD006895.

McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridioides difficile disease. Am J Gastroenterol. 2006;101(4):812-822.

Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a probiotic drug formulation. Clin Infect Dis. 2000;30(Suppl 2):S106-S109.

Pamer EG. Resurrecting the microbiota to combat antibiotic-resistant pathogens. Science. 2016;352(6285):535-538.

Seekatz AM, Pamer EG. Mechanisms of intestinal colonization resistance and associated diseases. Immunol Rev. 2014;260(1):23-39.

Lopetuso LR, Scaldaferri F, Petito V, et al. Commensal Clostridia: leading players in the maintenance of gut homeostasis. Gut Pathog. 2013;5(1):23.

Shen NT, Murch SJ, Shaikh N, et al. Probiotics for the prevention of Clostridioides difficile infection: a systematic review and meta-analysis. Ann Intern Med. 2017;167(2):104-113.

Górska A, Przystupski D, Niemczura MJ, et al. Postbiotics—a step beyond pre- and probiotics. Nutrients. 2019;8(4):189.

Tsilingiri K, Rescigno M. Postbiotics: what else? New developments in microbiome research. Gastroenterol Clin North Am. 2017;46(2):309-325.

Kakasis A, Panitsa G. Bacteriophage therapy as an alternative treatment for human infections: a comprehensive review. Int J Antimicrob Agents. 2019;53(1):16-21.

Górski A, Międzybrodzki R, Łusiak-Szelachowska M, et al. Bacteriophage therapy for the treatment of infections. Nat Rev Drug Discov. 2018;17(2):86-87.

Górski A, Międzybrodzki R, Łusiak-Szelachowska M, et al. Phage therapy: what have we learned in recent decades? Front Microbiol. 2018;9:3106.

Górski A, Międzybrodzki R, Łusiak-Szelachowska M, et al. Phage therapy: clinical applications. Adv Virus Res. 2018;100:93-142.

Górski A, Międzybrodzki R, Łusiak-Szelachowska M, et al. Phage therapy: what have we learned in recent decades? Front Microbiol. 2018;9:3106.